Roche Gets Priority Review for Immunotherapy Drug Tecentriq – Zacks.com
Tech Times |
Roche Gets Priority Review for Immunotherapy Drug Tecentriq
Zacks.com Roche Holding AG's (RHHBY – Free Report) Genentech announced that the FDA has accepted the company's supplemental Biologics License Application (sBLA) and granted Priority Review for cancer immunotherapy, Tecentriq, for the treatment of patients … FDA To Speed Up Review Of Roche Tecentriq As Immunotherapy Treatment For Bladder Cancer FDA Grants Genentech's Cancer Immunotherapy TECENTRIQ … FDA speeds up review of Roche's bladder cancer drug |
